Characteristics of pediatric adverse drug reaction reports in the Japanese Adverse Drug Event Report Database
Tóm tắt
There are no reports on investigations of the characteristics of adverse drug reaction (ADR) reports for pediatric patients in the Japanese Adverse Drug Event Report database (JADER) and the utility of database for drug safety surveillance in these patients. We aimed to evaluate ADR reports for pediatric patients in the JADER. We used spontaneous ADR reports included in the JADER since April 1, 2004, to December 31, 2017, which was downloaded in April 2018. In a total of 504,407 ADR reports, the number of spontaneous reports was 386,400 (76.6%), in which 37,534 (7.4%) were unknown age reports. After extraction of 27,800 ADR reports for children aged < 10 and 10–19 years, we excepted for ADR reports associated with a vaccine (n = 6355) and no-suspected drug reports (n = 86). A total of 21,359 (4.2%) reports were finally included in this analysis. More than half of the ADR reports were for children aged < 10 years. Approximately 30% of ADR reports had multiple suspected drugs, which did not differ by age. The percentages of fatal outcomes of ADRs among patients aged < 10 and 10–19 years were 4.7 and 3.9%, respectively. The most frequently reported drug, reaction, and drug-reaction pair were oseltamivir, abnormal behavior, and oseltamivir and abnormal behavior, respectively. We clarified the characteristics of ADR reports for Japanese children by using the JADER. ADR report databases, especially those for pediatric patients, are valuable pharmacovigilance tools in Japan and other countries. Therefore, a proper understanding of the characteristics of the ADR reports in the JADER is important. Additionally, potential signals for ADRs in pediatric patients should be monitored continuously and carefully.
Tài liệu tham khảo
de Bie S, Ferrajolo C, Straus SM, Verhamme KM, Bonhoeffer J, Wong IC, Sturkenboom MC; GRiP network. Pediatric Drug Safety Surveillance in FDA-AERS: A Description of Adverse Events from GRiP Project. PLoS One. 2015;10(6) e0130399.
CORDIS. Global Research in Paediatrics. [cited 2019 Nov 22]. Available from: https://cordis.europa.eu/project/rcn/97619/factsheet/en.
Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999;281:824829.
Kimland E, Rane A, Ufer M, Panagiotidis G. Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. Pharmacoepidemiol Drug Saf. 2005;14(7):493–9.
Hawcutt DB, Russell NJ, Maqsood H, Kouranloo K, Gomberg S, Waitt C, Sharp A, Riordan A, Turner MA. Spontaneous adverse drug reaction reports for neonates and infants in the UK 2001-2010: content and utility analysis. Br J Clin Pharmacol. 2016;82(6):1601–12.
Kaguelidou F, Beau-Salinas F, Jonville-Bera AP, Jacqz-Aigrain E. Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database. Br J Clin Pharmacol. 2016;82(4):1058–68.
Rosli R, Ming LC, Abd Aziz N, Manan MM. A retrospective analysis of spontaneous adverse drug reactions reports relating to paediatric patients. PLoS One. 2016;11(6):e0155385.
Aldea A, García Sánchez-Colomer M, Fernández Quintana E, Fernández Quintana E, García SM. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance system from 2004 to 2009. Eur J Clin Pharmacol. 2012;68(9):1329–38.
Obebi Cliff-Eribo K, Sammons H, Star K, Ralph Edwards I, Osakwe A, Choonara I. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012. Paediatr Int Child Health. 2016;36(4):300–4.
Kobayashi T, Noda A, Obara T, Tsuchiya M, Akasaka K, Yoshida M, Matsuura M, Sato M, Murai Y, Yamaguchi H, Tsuchiya F, Kihira K, Mano N. Knowledge, attitudes, and practice of hospital pharmacists regarding Pharmacovigilance and adverse drug reaction reporting in Japan. Hosp Pharm. (in press).
Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reactions in the UK. Arch Dis Child. 2002;87(6):462–6.
Cliff-Eribo KO, Sammons H, Choonara I. Systematic review of paediatric studies of adverse drug reactions from pharmacovigilance databases. Expert Opin Drug Saf. 2016;15(10):1321–8.
Li H, Guo XJ, Ye XF, Jiang H, Du WM, Xu JF, Zhang XJ, He J. Adverse drug reactions of spontaneous reports in Shanghai pediatric population. PLoS One. 2014;9(2):e89829.
Zopf Y, Rabe C, Neubert A, Hahn EG. Dormann H. Risk factors associated with adverse drug reactions following hospital admission: a prospective analysis of 907 patients in two German university hospitals. Drug Saf 2008;31(9):789–798.
Rashed AN, Wong IC, Cranswick N, Tomlin S, Rascher W, Neubert A. Risk factors associated with adverse drug reactions in hospitalised children: international multicentre study. Eur J Clin Pharmacol. 2012;68(5):801–10.
Knopf H, Du Y. Perceived adverse drug reactions among non-institutionalized children and adolescents in Germany. Br J Clin Pharmacol. 2010;70(3):409–17.
Yamada T, Watanabe Y, Kusama M, Sugiyama Y, Ono S. Factors associated with spontaneous reporting of adverse drug reactions in Japan. Pharmacoepidemiol Drug Saf. 2013;22(5):468–76.
Matsuda S, Aoki K, Kawamata T, Kimotsuki T, Kobayashi T, Kuriki H, Nakayama T, Okugawa S, Sugimura Y, Tomita M, Takahashi Y. Bias in spontaneous reporting of adverse drug reactions in Japan. PLoS One. 2015;10(5):e0126413.
Lebrun-Vignes B, Guy C, Jean-Pastor MJ, Gras-Champel V. Zenut M; French network of regional Centres of Pharmacovigilance and the French investigators for adverse skin reactions to drugs. Br J Clin Pharmacol. 2018;84(2):331–8.
Abe J, Umetsu R, Mataki K, Kato Y, Ueda N, Nakayama Y, Hane Y, Matsui T, Hatahira H, Sasaoka S, Motooka Y, Hara H, Kato Z, Kinosada Y, Inagaki N, Nakamura M. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese adverse drug event report database. J Pharm Health Care Sci. 2016;2:14.
Ban GY, Ahn SJ, Yoo HS, Park HS, Ye YM. Stevens-Johnson syndrome and toxic epidermal Necrolysis associated with acetaminophen use during viral infections. Immune Netw. 2016;16(4):256–60.
Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT. Surveillance for safety after immunization: vaccine adverse event reporting system (VAERS)--United States, 1991-2001. MMWR Surveill Summ. 2003;52(1):1–24.
Nomura K, Takahashi K, Hinomura Y, Kawaguchi G, Matsushita Y, Marui H, Anzai T, Hashiguchi M, Mochizuki M. Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. Drug Des Devel Ther. 2015;9:3031–41.